NCT04531826

Brief Summary

Anterior cruciate ligament (ACL) reconstruction is one of most commonly performed orthopaedic surgeries. Several options for graft choice are available and autologous single bundle hamstring graft is most commonly used. Variability exists among patients in terms of hamstring size, and therefore the graft diameter. Recently there has been an increasing amount of literature correlating the hamstring graft diameter with the graft failure rate \[1-4\]. They concluded that graft exceeding 8mm in diameter is associated with a significant lower risk of graft failure. There has been study showing that Asian patients were indeed 'different' from the Caucasians. Ho et al published his findings on Singaporean patients showing that the median graft diameters for female and male patients were 7mm and 8mm respectively \[5\]. A retrospective review our patients undergoing ACL reconstruction in our department over the past 10 years has shown that the mean graft diameter was 7.8mm (range, 5.5-10mm). The conventional way of four-strand hamstring autograft is done by doubling both the semitendinosus and gracilis tendons to provide a quadrupled graft. Several techniques have been described to increase the size of the hamstring graft. One of those is the -strand hamstring graft, in which the longer semitendinosus tendon is tripled with the shorter gracilis tendon doubled to produce a 5-strand configuration. We hypothesized that the 5-strand hamstring graft would provide a graft of significantly larger diameter than the conventional quadrupled autograft.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
62

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2021

Typical duration for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 26, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 31, 2020

Completed
4 months until next milestone

Study Start

First participant enrolled

January 1, 2021

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2022

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
Last Updated

August 31, 2020

Status Verified

August 1, 2020

Enrollment Period

2 years

First QC Date

August 26, 2020

Last Update Submit

August 26, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Mean graft diameter

    Intra-operative

Secondary Outcomes (3)

  • Adverse event

    Post-operative 3 months, 6 months, 9 months, 12 months, 18 months and 2 years.

  • ACL failure

    Post-operative 3 months, 6 months, 9 months, 12 months, 18 months and 2 years.

  • Clinical measures of knee function and structure

    Post-operative 3 months, 6 months, 9 months, 12 months, 18 months and 2 years.

Study Arms (2)

Group A

ACTIVE COMPARATOR

Five-strand hamstring autograft group

Other: 5-strand hamstring graft preparation

Group B

PLACEBO COMPARATOR

Quadripled hamstring autograft group

Other: 5-strand hamstring graft preparation

Interventions

Five-strand hamstring graft preparation

Group AGroup B

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age 18-50
  • Symptoms and physical examinations consistent with ACL deficiency and magnetic resonance imaging indicating ACL injury

You may not qualify if:

  • Previous surgeries in the operated knee
  • Revision ACL reconstruction
  • Contralateral ACL injury
  • Concomitant posterior cruciate ligament / collateral ligament surgeries in the operated knee

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Anterior Cruciate Ligament Injuries

Condition Hierarchy (Ancestors)

Knee InjuriesLeg InjuriesWounds and Injuries

Central Study Contacts

Keith Hay-Man Wan, FRCSEd (Orth)

CONTACT

Keith Hay-Man Wan, FRCSEd (Orth)

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Consultant

Study Record Dates

First Submitted

August 26, 2020

First Posted

August 31, 2020

Study Start

January 1, 2021

Primary Completion

December 31, 2022

Study Completion

December 31, 2023

Last Updated

August 31, 2020

Record last verified: 2020-08